• BD's Q4 FY26 adjusted diluted EPS jumped 27% year over year to $4.15.
• Revenue rose 5% year over year to $5.27 billion.
• The BD Liverty TIPS Stent Graft launched in the U.S. in Q1 FY27.
• FY27 adjusted diluted EPS guidance is $13.10 to $13.30, with adjusted operating margin expected to remain flat year over year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BD - Becton, Dickinson and Company published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.